Can upadacitinib treat eczema?

Upadacitinib (Upadacitinib) is an oral JAK1 inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults and adolescents 12 years of age and older with moderate to severe atopic dermatitis whose disease cannot be adequately controlled with other systemic drug products, including biologics, or when these therapies are not recommended. This is a symptom of eczema, a skin condition that causes dry, itchy skin and sometimes a red, scaly rash.

Moderate to severe atopic dermatitis is usually determined by skin involvement (the extent to which the surface of the body is affected) and the severity of symptoms (such as itching and rash), which cannot be controlled by topical medications alone. However, atopic dermatitis can be considered moderate or severe if the disease has a significant negative impact on the patient's quality of life, even if the affected body surface is more limited. Upadatinib inhibits immune system targets within cells, helping to combat the signs and symptoms of atopic dermatitis at the immune system level.

The original drug Upatinib has been launched in China, and has subsequently entered the scope of Class B medical insurance. Only eligible patients can be reimbursed. Specifications The price of each box of 15mg*28 tablets may be around RMB 3,000. The European version of the original drug sold overseas is priced at more than 20,000 yuan for 15mg*30 tablets (the price may fluctuate due to exchange rates), which is expensive. Cheaper upadatinib generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 15mg*30 tablets produced by Bangladesh pharmaceutical factory is around 900 yuan (the price may fluctuate due to the exchange rate).